| 0.54 0.01 (1.89%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.68 | 1-year : | 0.8 |
| Resists | First : | 0.58 | Second : | 0.68 |
| Pivot price | 0.5 |
|||
| Supports | First : | 0.44 | Second : | 0.36 |
| MAs | MA(5) : | 0.53 |
MA(20) : | 0.48 |
| MA(100) : | 0.52 |
MA(250) : | 0.66  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 74.5 |
D(3) : | 77.5 |
| RSI | RSI(14): 57.1 |
|||
| 52-week | High : | 1.13 | Low : | 0.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SSKN ] has closed below upper band by 20.2%. Bollinger Bands are 10% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.56 - 0.56 | 0.56 - 0.56 |
| Low: | 0.53 - 0.54 | 0.54 - 0.54 |
| Close: | 0.54 - 0.54 | 0.54 - 0.54 |
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems that are used for the treatment of psoriasis, vitiligo, acne, and other skin conditions. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
Tue, 23 Apr 2024
STRATA Skin Sciences to Present at the Planet MicroCap Showcase: Vegas 2024 - GlobeNewswire
Wed, 17 Apr 2024
Strata Skin Sciences, Inc. (SSKN) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Movies Canada
Tue, 09 Apr 2024
STRATA Skin Sciences renews international distribution deals By Investing.com - Investing.com
Tue, 09 Apr 2024
STRATA Skin Sciences Announces Renewal of Exclusive Distribution Agreements in China and Japan - GlobeNewswire
Mon, 01 Apr 2024
STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Q4 2023 Earnings Call Transcript - Yahoo Finance
Wed, 27 Mar 2024
STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2023 Earnings - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 35 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 4.2 (%) |
| Held by Institutions | 67.1 (%) |
| Shares Short | 215 (K) |
| Shares Short P.Month | 223 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.36 |
| Profit Margin | -32.5 % |
| Operating Margin | -13.4 % |
| Return on Assets (ttm) | -8.4 % |
| Return on Equity (ttm) | -62.8 % |
| Qtrly Rev. Growth | -18 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.95 |
| EBITDA (p.s.) | -0.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -1.75 |
| PEG Ratio | -0.2 |
| Price to Book value | 1.5 |
| Price to Sales | 0.56 |
| Price to Cash Flow | -36.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|